What You Should Know:
– Theator, the first-of-its-kind AI-driven Surgical Intelligence Platform, announced that it has extended its Series A funding round by $24M, bringing the round’s total to $39.5M
– The extension was led by Insight Partners with support from existing investors including Blumberg Capital, Mayo Clinic, NFX, StageOne Ventures, iAngels, and former Netflix Chief Product Officer Neil Hunt. In addition, new growth investors including iCON and TripActions’ CEO and Co-founder Ariel Cohen joined the round.
AI-Driven Surgical Improvement Models
Theator, the creator of Surgical Intelligence, announced today that it has raised $24M in an extension of its Series A funding round. This extension follows an initial $15.5M Series A round announced in February 2021, bringing the round total to $39.5M.[FP1] The extended funding round was once again led by Insight Partners
Theator is pioneering Surgical Intelligence to eliminate the paradigm that where you live determines if you live. Theator’s Surgical Intelligence Platform institutionalizes the routine capture of surgical video data, harnessing AI and computer vision to automatically analyze every operation. Surgical Intelligence generates actionable insights that optimize patient outcomes, ultimately raising the standard of patient care. Theator’s unrivaled library of surgical video and data contains over 30K hours of video, with nearly a billion frames analyzed.
With this Series A extension, Theator has raised $42.5M to date. Since its initial Series A round last year, Theator has collaborated with Mayo Clinic and partnered with the Canadian Association of General Surgeons (CAGS), adding further prestige to the burgeoning list of innovative medical institutions and surgical societies adopting Surgical IntelligenceThe additional investment will be used to continue Theator’s commercial expansion and accelerate the rollout of its Surgical Intelligence Platform in operating rooms and healthcare systems across North America. The series extension comes on the heels of significant commercial traction, including Theator’s expansion into Urology earlier this year.
“This funding is a strong vote of confidence in our vision, team, and the field of Surgical Intelligence as the cornerstone of the future of surgery,” said Dr. Tamir Wolf, CEO and Co-founder of Theator. “Surgical Intelligence is already demonstrating significant improvement in surgical quality and safety. It’s thrilling to hear about the impact our partners and collaborators have achieved thus far, and we look forward to this latest investment advancing our mission to transform surgery and alleviate variability and disparity in surgical care worldwide.”
